Pepex Biomedical,

Pepex Biomedical, Inc. (“Pepex” or the “Company”) is medical device contract development and manufacturing organization (CDMO) focused exclusively on the design and manufacture of electrochemical biosensors. After years of R&D, the Company is prepared to commercialize its industry-disruptive technology through a potential wide range of diagnostic test product use cases. At present, Pepex has been awarded an extensive Intellectual Property (IP) portfolio consisting of +300 global patents that protect its proprietary manufacturing processes and biosensor designs capable of identifying hundreds of unique biomarkers which indicate the presence, and in some cases the concentration level, of cancers, lactic acid, sepsis, Alzheimer’s, HIV, Ebola, hepatitis, Traumatic Brain Injury (TBI), tuberculosis, CV-19, and other life-altering conditions quickly, easily, and cost effectively in saliva, blood, and interstitial fluid. The Company’s biosensor technologies are referred to individually as Composite Conductive Monofilament (CCM®), 3 Electrode (3E™), and Lansing Sensor (LS®), and collectively referred to as Pepex Biosensor Technologies (PBT). These innovative systems integrate from 1 to many polyetheretherketone (PEEK) fibers, each roughly the size of a human hair, which can be positioned inside a physical space as small as a 32-guage cannula. Using the Company’s patented three-dimensional, nanoparticle Aerosol Jet Printing (AJP) techniques, analyte-specific chemistry is applied to the PEEK fibers which may be inserted into a range of various sizes and form factors for specific use cases. As a matter of reference, initial FDA clearance on an early biosensor design was formerly secured through predicate device submission. Recently, the Company has also developed its AnalyteAI™ artificial intelligence competency which may be applied to provide near real-time data analysis of diagnostic samples.